Vise Technologies Inc. Acquires 4,330 Shares of Eli Lilly and Company (NYSE:LLY)

Vise Technologies Inc. grew its position in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 57.2% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 11,896 shares of the company's stock after purchasing an additional 4,330 shares during the period. Eli Lilly and Company makes up about 0.8% of Vise Technologies Inc.'s investment portfolio, making the stock its 23rd largest position. Vise Technologies Inc.'s holdings in Eli Lilly and Company were worth $9,184,000 at the end of the most recent reporting period.

Other hedge funds also recently made changes to their positions in the company. Retirement Planning Group LLC raised its position in shares of Eli Lilly and Company by 5.2% during the 4th quarter. Retirement Planning Group LLC now owns 364 shares of the company's stock valued at $281,000 after acquiring an additional 18 shares in the last quarter. Pinnacle Wealth Management LLC boosted its stake in Eli Lilly and Company by 34.0% during the 4th quarter. Pinnacle Wealth Management LLC now owns 1,771 shares of the company's stock valued at $1,367,000 after purchasing an additional 449 shares during the period. Headinvest LLC grew its position in Eli Lilly and Company by 13.2% in the 4th quarter. Headinvest LLC now owns 790 shares of the company's stock worth $610,000 after purchasing an additional 92 shares during the last quarter. Gordian Capital Singapore Pte Ltd increased its stake in shares of Eli Lilly and Company by 58.3% in the fourth quarter. Gordian Capital Singapore Pte Ltd now owns 1,290 shares of the company's stock valued at $997,000 after purchasing an additional 475 shares during the period. Finally, City National Bank of Florida MSD bought a new stake in shares of Eli Lilly and Company during the fourth quarter valued at approximately $626,000. Hedge funds and other institutional investors own 82.53% of the company's stock.

Eli Lilly and Company Trading Up 1.5%

NYSE LLY traded up $10.91 on Tuesday, hitting $724.62. 1,683,681 shares of the stock were exchanged, compared to its average volume of 3,615,114. Eli Lilly and Company has a 52-week low of $677.09 and a 52-week high of $972.53. The company has a debt-to-equity ratio of 2.00, a current ratio of 1.15 and a quick ratio of 0.97. The company has a market capitalization of $686.74 billion, a price-to-earnings ratio of 61.91, a P/E/G ratio of 1.40 and a beta of 0.48. The company's 50-day moving average price is $786.82 and its two-hundred day moving average price is $802.40.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its earnings results on Thursday, May 1st. The company reported $3.34 earnings per share for the quarter, missing analysts' consensus estimates of $4.64 by ($1.30). The business had revenue of $12.73 billion during the quarter, compared to analyst estimates of $12.77 billion. Eli Lilly and Company had a net margin of 23.51% and a return on equity of 85.24%. Eli Lilly and Company's revenue for the quarter was up 45.2% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.58 EPS. Research analysts predict that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 10th. Stockholders of record on Friday, May 16th will be issued a dividend of $1.50 per share. This represents a $6.00 annualized dividend and a dividend yield of 0.83%. The ex-dividend date of this dividend is Friday, May 16th. Eli Lilly and Company's dividend payout ratio is currently 48.82%.

Wall Street Analyst Weigh In

LLY has been the topic of several analyst reports. UBS Group lowered their target price on Eli Lilly and Company from $1,100.00 to $1,050.00 and set a "buy" rating on the stock in a research report on Friday, May 2nd. Truist Financial raised their price target on Eli Lilly and Company from $1,029.00 to $1,038.00 and gave the company a "buy" rating in a report on Monday, February 3rd. Hsbc Global Res downgraded shares of Eli Lilly and Company from a "strong-buy" rating to a "moderate sell" rating in a report on Monday, April 28th. Wells Fargo & Company reiterated an "overweight" rating on shares of Eli Lilly and Company in a research report on Thursday, May 1st. Finally, Cantor Fitzgerald initiated coverage on shares of Eli Lilly and Company in a research note on Tuesday, April 22nd. They issued an "overweight" rating and a $975.00 price target for the company. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and eighteen have assigned a buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $1,011.37.

Insider Activity

In related news, CAO Donald A. Zakrowski sold 1,000 shares of the business's stock in a transaction that occurred on Thursday, March 13th. The stock was sold at an average price of $818.24, for a total value of $818,240.00. Following the completion of the sale, the chief accounting officer now owns 5,840 shares of the company's stock, valued at approximately $4,778,521.60. The trade was a 14.62% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. 0.13% of the stock is currently owned by corporate insiders.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.